Strategic partnerships BioConnection collaborates with clinical and industrial partners for drug product manufacturing, indicating ongoing demand for contract manufacturing, process development and transfer capabilities that could be expanded with targeted outreach to new biotech and pharma players.

Scale and expertise With capabilities from toxicology materials to Phase III clinical material and final market production up to 500 L, BioConnection presents a full-spectrum CMO offering suitable for companies seeking scalable, compliant injectable and lyophilized fill finish solutions.

Awards and leadership Recent European awards and key leadership hires bolster credibility and signal growth, providing a compelling narrative for outreach to potential customers seeking proven quality, governance, and strategic guidance.

Growth through partnerships Strategic collaborations with industry peers (for example AGC Biologics) show a track record of joint programs, suggesting opportunities to propose co-development or end-to-end manufacturing partnerships for bioscience and biologics programs.

Market readiness FDA and EMA-certified facilities, combined with a focus on personalized medicine and small-scale hand-fill capabilities, position BioConnection to target emerging biotech firms and niche indications that require flexible, compliant manufacturing and quick tech transfers.